Clinical Trial Update: Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis [Phase 3]

View source ↗

Summary

Phase 3 trial comparing daclizumab high-yield process (BIIB019) with interferon beta-1a in relapsing-remitting multiple sclerosis reports efficacy and safety re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Zinbryta (daclizumab high yield process)

Snippet

Sponsor: Biogen | Conditions: Relapsing-Remitting Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2016-07-11